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Abstract 42 
Background 43 
Shared decision making is a stated aim of several healthcare systems. In the area of cancer, patients’ 44 
views have informed policy on screening and treatment but there is little information about their 45 
views on diagnostic testing in relation to symptom severity. 46 
Methods 47 
We used the technique of willingness-to-pay to determine public preferences around diagnostic 48 
testing for colorectal, lung, and pancreatic cancer in primary care in the UK. Participants were 49 
approached in general practice waiting rooms and asked to complete a two-stage electronic survey 50 
that described symptoms of cancer, the likelihood that the symptoms indicate cancer, and 51 
information about the appropriate diagnostic test. Part 1 asked for a binary response (yes/no) as to 52 
whether they would choose to have a test if it were offered. Part 2 elicited willingness-to-pay values 53 
of the tests using a payment scale followed by a bidding exercise, with the aim that these values 54 
would provide a strength of preference not detectable using the binary approach.  55 
Results 56 
A large majority of participants chose to be tested for all cancers, with only colonoscopy (colorectal 57 
cancer) demonstrating a risk gradient. In the willingness-to-pay exercise participants placed a lower 58 
value on an X-ray (lung cancer) than the tests for colorectal or pancreatic cancer and X-ray was the 59 
only test where risk was clearly related to the willingness-to-pay value.  60 
Conclusion 61 
Willingness-to-pay values did not enhance the binary responses in the way intended; participants 62 
appeared to be motivated differently when responding to the two parts of the questionnaire. More 63 
work is needed to understand how participants perceive risk in this context and how they respond to 64 
questions about willingness-to-pay. Qualitative methods could provide useful insights.  65 
 66 
Keywords: willingness-to-pay; cancer; diagnostic tests; primary health care 67 
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 68 
Background 69 
Shared decision making is a stated aim of several healthcare systems [1,2]. Involving patients in 70 
critical decisions about their care is regarded as not only ethically correct but also as a way of 71 
improving quality and “avoiding unwanted and costly medical interventions” [3]. In the UK the 72 
philosophy of “no decision about me, without me” has been promoted by the Department of Health 73 
[4] and has been applied to many aspects of patient care. However, fully shared decisions can only 74 
be made if the asymmetry of information between clinicians and patients is more balanced. 75 
Recently, the current imbalance has begun to shift, encouraged by a greater will on the part of 76 
clinicians and an increase in readily available information accessible to patients, both from the 77 
National Health Service (NHS) and elsewhere. 78 
 79 
One notable area where shared decision making has been adopted actively is cancer. Research on 80 
patients’ views has informed policy on screening [5] and treatment [6] in accordance with referral 81 
guidelines developed by the National Institute for Health and Care Excellence (NICE) [7]. Such 82 
information is important, as care plans that incorporate patients’ preferences are more likely to be 83 
successful in terms of acceptability and may lead to more efficient use of resources. However, one 84 
gap in the evidence is information about patients’ views on testing for cancer with respect to risk: 85 
how serious do symptoms have to be, in terms of indicating cancer, for patients to consider a 86 
particular test to be worthwhile? The lifetime prevalence of cancer in the UK is more than 30% [8] 87 
and despite falling death rates the fear of cancer is known to be high among the general population 88 
[9]. Early diagnosis may improve survival [10] but many early symptoms of cancer, for example, 89 
cough, diarrhoea, and headache, far more often indicate a benign condition. General practitioners 90 
are faced with the challenge of deciding which patients with such symptoms to refer for diagnostic 91 
testing, relying largely on their expertise and limited national guidelines [7]. The risk of failing to 92 
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investigate a potentially serious symptom has to be weighed against the need to avoid unnecessary 93 
anxiety, inconvenience, side-effects and cost from inappropriate investigation. 94 
 95 
The study described here is part of a larger study reported more fully elsewhere [11], which used a 96 
survey of primary care attenders to investigate preferences for cancer investigation. Three 97 
contrasting cancers were chosen as exemplars - colorectal, lung and pancreas – because of their 98 
variation in symptoms, type and accessibility of test, treatment, and prognosis. Here, we describe a 99 
willingness-to-pay component of the survey, which was designed to enhance the results of the main 100 
survey: if the same number of participants opted to be investigated for a particular cancer 101 
irrespective of risk level, could the values offered in the willingness-to-pay exercise be used to refine 102 
these responses and identify a threshold risk level below which testing was not regarded as 103 
worthwhile. 104 
 105 
Willingness-to-pay has been used extensively to obtain patient and public valuations for a variety of 106 
goods and services in many diverse settings.[12] Despite considerable methodological research into 107 
the use of different willingness-to-pay techniques [13] no consensus has emerged as to best practice 108 
and it is likely that different methods suit different situations and patient groups [14, 15]. The 109 
simplest form of value elicitation is to use an ‘open-ended’ approach whereby the respondent is 110 
asked to provide a valuation without any prompting or context; more sophisticated, is a ‘payment 111 
scale’ approach where a list of feasible values is offered and the respondent chooses from the list.  A 112 
bidding approach, which is more refined, has generally come to be preferred to both of these. [16, 113 
17] This method requires the respondent to accept or reject a starting bid (value), which is increased 114 
or decreased according to the response and the process continues until a final value is determined. 115 
Although this is often a preferred method there is evidence suggesting that responses in a bidding 116 
approach tend towards the point at which the bidding starts (starting point bias) [18, 19, 20]. This 117 
can lead to biased results.  118 
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 119 
The aim of this study was to develop and administer a willingness-to-pay questionnaire that could be 120 
used to elicit the relative values that patients place on diagnostic testing for lung, pancreatic and 121 
colorectal cancers. We aimed to identify a risk threshold for each cancer that would indicate when 122 
patients choose to be tested in preference to watchful waiting. 123 
 124 
 125 
Methods 126 
Study design 127 
We developed a vignette-based survey with a willingness-to-pay component to determine the 128 
likelihood that patients would choose to be tested for colorectal, lung, and pancreatic cancer, using 129 
various levels of risk. The key question of what proportion of the population would choose to be 130 
tested at each risk level for each cancer was addressed using a simple ‘yes’/’no’ alternative. Those 131 
responding ‘yes’ to a test proceeded to a willingness-to-pay exercise with the aim of identifying a 132 
strength of preference around the binary choice. Cookson suggests that willingness-to-pay exercises 133 
that aim to elicit true, absolute values are unreliable because of “budget constraint bias”, where the 134 
value given is inflated because of the close focus placed on a particular service [21]; comparative 135 
willingness-to-pay may be a way of avoiding this. This study adopted the latter technique, with the 136 
aim of identifying relative values to differentiate between ‘yes’ responses by risk level. The survey 137 
was designed specifically for this study and was administered using an electronic touch screen tablet 138 
computer (an iPad). The iPad application software was custom built, which gave us considerable 139 
scope and flexibility in the design. We obtained ethics approval from the South West (Southmead) 140 
National Research Ethics Service committee (ref 11/SW/0055). Participants provided oral informed 141 
consent. 142 
 143 
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Survey design 145 
The survey contained three components. The first section asked for information about participant 146 
characteristics, including age, sex, income, education, employment status, ethnicity, experience of 147 
cancer (self and family member or close friend), and convenience of the nearest main hospital. 148 
Screen shots showing details of the way these questions were asked are included in Appendix A. 149 
 150 
Secondly, we used vignettes to ascertain participants’ attitudes towards testing for cancer. We 151 
developed twelve separate vignettes, one for each combination of the three cancers (colorectal, 152 
lung, and pancreas) and four different risk levels (1%, 2%, 5%, 10%). The content of the vignettes 153 
was informed by current guidelines and clinical experts on the team. We also undertook qualitative 154 
interviews with patients referred for symptoms suspicious of cancer [22], and these were used to 155 
validate the vignettes’ depiction of the three diagnostic pathways as experienced by patients. Each 156 
vignette contained a description of symptoms, the chance that these might indicate cancer – 157 
presented as a percentage, ratio, and pictorially – information about the diagnostic test that would 158 
be used, likely treatment, and an indication of the prognosis. The information provided in the 159 
vignettes is summarised in Table 1.  For each participant, one of the twelve vignettes was generated 160 
randomly, thus avoiding any ordering effect, and the respondent was asked to imagine they were in 161 
the situation described in the scenario. They were then asked whether they would choose to have 162 
the diagnostic test if it were offered.  163 
 164 
Following a ‘yes’ response to the question about testing, participants proceeded automatically to the 165 
third section of the survey – the willingness-to-pay exercise. The design of this part of the survey was 166 
informed by experts in the team and with reference to published costs of tests. The survey and the 167 
values included were tested on a sample of participants using the technique of verbal probing [23] to 168 
check that respondents interpreted the question correctly, and understood why it was being asked. 169 
Two rounds of verbal probing were carried out, the first on 13 participants and the second on five. 170 
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Further pilot testing ensured that the exercise would not be too burdensome. Feedback from the 171 
verbal probing was used to refine the content: data from the first round indicated that respondents 172 
did not fully understand the concept of opportunity cost so the wording was changed to convey the 173 
idea of sacrifice. Subsequent testing in round 2 showed this change was successful. To mitigate 174 
starting point (or anchoring) bias we designed a two-part exercise in which respondents were first 175 
presented with a payment scale and the response to that question established the starting point of a 176 
bidding process. The starting point was generated randomly from a selection within the range of the 177 
scale chosen, and the participants could then bid up or down from the starting point. This 178 
mechanism is illustrated in Figure 1, using an example where a participant selects the payment scale 179 
£101 to £300. The starting point for the bidding is randomly selected by the software from £125, 180 
£200, £250 and £300; in this example £200 is selected. The participant is then able to bid up as far as 181 
£300 or down to below £125, with five possible end points. In total, 18 end points were used, five for 182 
each of the lower three bands (£1 to £100, £101 to £300, and £301 to £700) and three for the “more 183 
than £700” band. Within each band, the difference between each end point and the one 184 
immediately higher increased as the value increased so that proportional differences were roughly 185 
similar [24].  186 
 187 
At the beginning of the task, when presenting the payment scales, we used reference goods to help 188 
participants think about the value of a diagnostic cancer test (see Figure 2). We chose a selection of 189 
‘lifestyle’ goods and services, seen as being ‘desirable’ though not essential, and which could 190 
conceivably be sacrificed to pay for healthcare. Wording was carefully chosen to encourage them to 191 
think in terms of sacrifice – that is, what they might be prepared to give up or go without in order to 192 
have a test [25]. 193 
 194 
It is known that some individuals find it hard to place a value on healthcare, particularly in the 195 
context of a system of universal coverage as in the UK, and moreover some individuals feel it is 196 
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unethical to expect them to provide a valuation. To accommodate these views the payment scale 197 
offered an option of “I would not pay anything for the test”. If this was selected they were then 198 
asked a further question about their reason for this view with the choices of “I cannot afford 199 
anything extra”, “I do not believe I should pay for healthcare”, and “It is too difficult to put a value 200 
on health”. 201 
 202 
Throughout the development of the survey we piloted the wording and layout of all components 203 
with a patient and public involvement group using the technique of verbal probing [23]. Feedback 204 
from these sessions was used to refine and improve the content.  205 
 206 
Survey Administration 207 
The survey was administered by researchers in general practice waiting areas. We targeted a 208 
susceptible population – that is, those at greater risk of cancer who would be likely to seek health 209 
care help and advice (GP attenders aged 40 and over). General practices in three geographical areas 210 
(Bristol & South Gloucestershire, Devon, and the East of England) were included and practices were 211 
purposively sampled to achieve an overall mix of urban and rural, and a range of socio-economic 212 
statuses. Data collection took place at 26 practices at different times of the day and week between 213 
December 2011 and August 2012.  214 
 215 
Participants could complete up to three vignettes, one for each cancer. The first vignette was 216 
randomly generated from all 12 possibilities (three cancers, four risk levels), the second from the 217 
eight that related to the two remaining cancers, and the third from the four relating to the final 218 
cancer.  219 
 220 
When data collection was complete we conducted a test-retest exercise in a different practice using 221 
a convenience sample of 48 volunteers who agreed to return two weeks later. The random 222 
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generation of vignettes was removed from the survey for the second stage of this exercise to ensure 223 
the two tests were identical.  224 
 225 
Analysis 226 
Data were electronically downloaded directly from the iPads at the end of each session. Participant 227 
characteristics were explored descriptively and the age/sex profile was compared with that of 228 
England as a whole and general practice attenders. Responses to the choice of whether to be tested 229 
were analysed descriptively and using logistic regression to establish the extent to which risk played 230 
a part in participants’ decisions.  231 
 232 
The data from the willingness-to-pay exercise were analysed to explore whether they could be used 233 
to inform the strength of preference about the simple ‘yes’/’no’ choice. We therefore investigated 234 
the extent to which willingness-to-pay values differed according to risk. We explored this 235 
descriptively using means and medians, and tested the relationship between the willingness-to-pay 236 
values and risk using regression analysis. A one-way analysis of variance, with three degrees of 237 
freedom, was conducted to investigate the difference in mean willingness-to-pay across all risk 238 
levels, for each cancer. 239 
 240 
Analysis was carried out using Stata v13.1 statistical software and Microsoft Office Excel 2013. 241 
 242 
Results 243 
Participant characteristics 244 
A total of 3,469 participants took part, completing 6,930 vignettes. The characteristics of the 245 
participants are shown in Table 2. The age/sex profile of responders is similar to that of the 246 
consulting population in England [26]. As expected, when compared with the general population of 247 
England the sample was under-represented in terms of younger men (17% vs 27% aged 40-59), and 248 
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over-represented in respect of older women (15% vs 11% aged 60-69), and for all elderly people 249 
(29% vs 24% aged 70 and over) [27]. The respondents were: largely white British; nearly half were 250 
retired; 15% had previously been diagnosed with cancer; and 75% had a family member or close 251 
friend who had experienced cancer. 252 
 253 
Binary responses 254 
Detailed results of the responses to the ‘yes’/’no’ question about whether to opt for a test have 255 
been reported elsewhere [11]. Table 3 shows the number of participants choosing to be investigated 256 
at each risk level for each cancer. A large majority (88%) of participants chose to be referred for a 257 
test; this was slightly lower in the low risk (1%) group and higher in the high risk (10%) group, but the 258 
difference was very small (87% vs 89%). Colonoscopy (colorectal cancer) had a lower uptake than 259 
chest X-ray (lung cancer) and ultrasound/CT scan (pancreatic cancer) and displayed the greatest risk 260 
gradient. These observations were confirmed by the results of the logistic regression analysis, which 261 
controlled for patient characteristics.  262 
 263 
Willingness-to-pay 264 
The results of the willingness-to-pay exercise are presented in Tables 4-6. Table 4 gives the number 265 
and percentage of participants who selected each payment scale, by cancer and by risk level and 266 
Table 5 gives the values indicated in the bidding exercise. Results for each cancer separately are 267 
based on all responses, but because participants could respond to up to three vignettes, results for 268 
all cancers together use each participant’s first response so as to reduce differential selection bias. 269 
Responses covered the entire payment range offered for all cancers and all risk levels, though 68% of 270 
participants bid up to the highest value within the range of the payment scale chosen. 271 
 272 
The results show that participants placed a lower value on an X-ray for lung cancer than the tests for 273 
colorectal or pancreatic cancer; the regression analysis in Table 6, which shows the best-fit logistic 274 
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regression models, indicate that controlling for other factors there was a difference of about £51 275 
(95% CI: £14 to £87) in the mean willingness-to-pay between an X-ray and a colonoscopy and slightly 276 
less between an X-ray and the tests for pancreatic cancer. In general, testing was valued more highly 277 
when risk was high than when it was low, though the increase is not monotonic in the case of 278 
colorectal and pancreatic cancers (Tables 5 and 6). This may be related to the lack of a clear gradient 279 
for these two, as evidenced by testing for a difference in mean willingness-to-pay by risk level (p-280 
values: colorectal 0.71; pancreas 0.91). 281 
 282 
Around one fifth of respondents chose “I would not pay anything” when completing the payment 283 
scale exercise. Of these, one half said they did not believe they should pay for health care and one 284 
third said they could not afford to pay. Comparing the lowest risk level (1%) with the highest (10%), 285 
more individuals reported not being able to pay at the higher level (32% vs 26%) and more said they 286 
did not think they should pay at the lower level (59% vs 52%). 287 
 288 
Factors influencing responses to individual cancers 289 
Previous analysis of responses to the ‘yes/no’ question of whether participants chose to be tested 290 
indicated that age was an important factor in all three cancer models [11]. Other variables affecting 291 
this decision were travel time to nearest hospital (colorectal and lung), whether a family member or 292 
close friend had previously been diagnosed with cancer (colorectal and lung) and income (colorectal 293 
and pancreas). The willingness-to-pay exercise indicated a rather different set of variables 294 
influencing the values placed on the tests: age did not appear as a factor in any of the three models 295 
and neither did travel time (Table 6). Three variables did however contribute to the willingness-to-296 
pay values in all three tests: those with a higher income, particularly those in the highest bracket, 297 
were prepared to pay more for testing, as were the more highly educated, and a previous diagnosis 298 
of cancer increased the valued placed on a test by between £63 (95% CI: £13 to £114) (lung) and £73 299 
(95%CI: £22 to £124) (colorectal). Additionally, the values placed on an X-ray for lung cancer were 300 
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affected by a family member or close friend having been diagnosed with cancer and employment 301 
status. Males were prepared to pay more for testing for pancreatic cancer than were women. 302 
 303 
Test-retest  304 
Analysis of the test-retest data suggested a good level of agreement in terms of the binary choice 305 
question: 47 (99%) of the 48 who took part gave the same response as to whether they would 306 
choose to be tested. The level of agreement for both parts of the willingness-to-pay element was 307 
lower. Forty-three of the 48 respondents entered the willingness-to-pay exercise on both occasions 308 
and chose a payment scale.  Of these, 25 (58%) chose the same band on both occasions. Forty-two 309 
participants gave two valid willingness-to-pay values from the bidding process and 14 (33%) gave the 310 
same exact value at re-test. 311 
 312 
Discussion 313 
Key findings 314 
The aim of this willingness-to-pay exercise was to enhance the responses to a simple ‘yes’/’no’ 315 
question about testing for cancer, by indicating a strength of preference. We hypothesised that we 316 
might be able to identify a threshold level of risk below which patients would prefer to wait and see 317 
how symptoms develop before being referred for further investigation. Although the overwhelming 318 
majority of respondents opted for testing for the three cancers at all levels of risk included, the 319 
responses to the willingness-to-pay exercise did not augment the results of the binary question as 320 
anticipated; in fact the results suggest that participants treated the two parts of the survey rather 321 
differently.  The ’yes’/’no’ component of the survey indicated a risk gradient in the case of colorectal 322 
cancer, which was not seen in the willingness-to-pay values given to pay for a colonoscopy, but there 323 
was evidence that risk influenced willingness-to-pay values for testing for lung cancer. Furthermore, 324 
the participant characteristics that affected the decision to opt for a test were different than those 325 
affecting the willingness-to-pay values.  326 
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 327 
Explanations for the findings 328 
In general, the willingness-to-pay values obtained did not differentiate across risk levels as much as 329 
hypothesised. It is possible that the known “fear of cancer” may have contributed to this, indeed this 330 
was indicated in the yes/no part of the questionnaire where results suggested that patients would 331 
opt for testing even at very low levels of risk. 332 
The willingness-to-pay values obtained suggest that risk is an important consideration when patients 333 
are deciding whether to accept the offer of a test for cancer of the lung but not colorectal or 334 
pancreas, a finding at odds with those of the binary ‘yes’/’no’ decision, where risk was only evident 335 
in colorectal cancer. Colorectal cancer involves the most invasive test, which may explain this 336 
finding, but it would seem that in the willingness-to-pay exercise participants may have 337 
discriminated according to neither the burden of the test nor the prognosis (pancreatic cancer 338 
having the worst likely outcome), but possibly their perception of the cost of the test. They valued a 339 
chest X-ray more highly if the risk of cancer was high (£365 at 10% risk) and lower if the risk was low 340 
(£305 at 1% risk) and there was a clear gradient (p-value 0.049). This was not the case with the more 341 
expensive tests where there was no evidence of an overall gradient despite the value placed on a CT 342 
scan for pancreatic cancer at the 10% risk level being somewhat higher than the value at 1%. The 343 
tests were described in detail in the vignettes so it is possible that many participants recognised that 344 
a chest x-ray is less costly than a colonoscopy and a CT scan. This confirms the belief that willingness-345 
to-pay questions tend not to be sensitive to the size or scope of benefits [28] but is counter to the 346 
finding that people tend to state a similar amount for any reduction in risk of death or injury [29].     347 
  348 
This raises the question of what people are actually valuing when they answer a willingness-to-pay 349 
question. Our hypothesis was that the willingness-to-pay exercise could be used to discriminate 350 
between cancers and risk levels more sensitively than a binary choice of whether to be tested or not. 351 
However, it would seem that participants viewed the two parts of the questionnaire separately and 352 
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differently: the initial choice of whether to be tested appears to have been driven by the burden 353 
placed on them in undergoing the diagnostic test, illustrated by greater reservation about agreeing 354 
to a colonoscopy than the other tests, whereas the willingness-to-pay component appears to reflect 355 
people’s perception of the cost burden of the test, as a chest X-ray is by far the least expensive of 356 
the three. While the main aim of our study was to make comparisons across cancers and risk levels it 357 
is useful to reflect on the absolute levels of the willingness-to-pay values in comparison to those 358 
found in similar studies. Marshall et al [5] compared physician and patient preferences for different 359 
methods of screening for colorectal cancer in Canada and the US. The values obtained ranged from 360 
US$111 (equivalent to £245 inflation adjusted) to C$232 (£662) depending on the type of test and in 361 
another US-based study to determine the value of time and discomfort of a colonoscopy, Jonas et al 362 
[30] reported a mean value of US$263 (£563). In the UK Frew et al [31] compared different methods 363 
of eliciting the willingness-to-pay for a faecal occult blood (FOB) test and a flexible sigmoidoscopy 364 
(FS) for colorectal cancer screening with results ranging from £86 (£136, inflation adjusted) for FS to 365 
£130 (£205) for FOB. In comparison to this, Nuemann et al [32] obtained somewhat higher values in 366 
their US study for predictive testing: for breast and prostate cancer these ranged from US$508 367 
(£904) for an imperfect test for breast cancer when the risk is 10% to US$622 (£1007) for a perfect 368 
test for prostate cancer when the risk is 25%. Our results of £305 to £393 across all cancers and risk 369 
levels fall towards the lower end of these, closer to the UK study results than those from North 370 
America.            371 
 372 
Methodological considerations 373 
A variety of willingness-to-pay methods have been used in different settings and different patient 374 
groups [12]. In this study we used a bidding approach; furthermore, to mitigate the effect of any 375 
possible starting point bias we employed a two-part approach with each participant effectively 376 
selecting their own starting point. To our knowledge, this is a novel approach, made possible 377 
because of the mode of administration and the electronic nature of the questionnaire. However, in 378 
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avoiding one methodological difficulty we have arguably introduced another. The bidding exercise 379 
was designed to restrict participants to the boundaries of the payment scale they chose in the first 380 
part of the willingness-to-pay exercise. This decision was largely driven by concern over ethics: it was 381 
considered ‘unfair’ to allow respondents to bid above/below the top/bottom value of the scale they 382 
had chosen. In fact, we found that 68% of participants bid up to the highest value, leaving the 383 
unanswered question of what would have happened if they had been allowed to go beyond that 384 
value. This, in part, may explain the poor result in the relevant part of the test-retest exercise 385 
because once the participant had chosen a different payment scale in the retest, which 40% did, it 386 
was impossible for them to identify the same final value as in the initial exercise.   387 
 388 
In designing our study we were conscious of the phenomenon of ‘prominent’ numbers and we felt 389 
that the two-part design might mitigate this. In fact, analysing the results of the test-retest exercise 390 
we found that all participants who chose exactly the same vale on both occasion had chosen a 391 
‘prominent’ number: £0, £100, £300, £700 or £1000. This highlights the need for a better 392 
understanding of the role of ‘prominent’ numbers in such studies and has implications for the design 393 
of future studies. 394 
 395 
We included reference goods in the payment scale exercise to help participants think about the 396 
value of a test. The verbal probing exercise did not throw up any consensus concerns about the use 397 
of reference goods or the choice of goods but there were some interesting individual comments: 398 
“You are given a few ideas to give you the value of the cost”, “I think health is more important than 399 
material things” and “At my age we already have most things we need – furniture etc.” However, 400 
when asked how easy or hard it was to put a value on the test none of the respondents mentioned 401 
that the reference goods helped. Whilst it seems useful to have benchmark reference goods for 402 
respondents to use our experiences suggest these are not essential; if they are included they must 403 
be chosen carefully and must be relevant to the population being surveyed. 404 
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 405 
 406 
 407 
Limitations 408 
The technique of willingness-to-pay is a conceptually attractive method of eliciting valuations and 409 
preferences. If responses reflect the true value that a population places on an intervention such as 410 
diagnostic testing the value can be compared with cost in a ‘purer’ way than any other outcome and 411 
used to make decisions about allocative efficiency. However, the results of this study show that 412 
many people find it difficult to think in terms of the value of benefit offered rather than what the 413 
intervention involves, and this is likely to be particularly true in a system of universal health 414 
insurance such as the NHS in England. While we were unable to use the results of this study as 415 
intended, they do reveal interesting unanswered questions which should be explored further. 416 
Qualitative methods could be employed to understand more about the thought processes and 417 
motivation of respondents as they complete such a survey; although some limited work has been 418 
done in this area [24, 33] there is a clear gap in our knowledge that needs to be closed in order to 419 
successfully exploit the full potential of willingness-to-pay as a technique for eliciting true valuations. 420 
 421 
Conclusion 422 
The willingness-to-pay exercise reported here successfully obtained valuations for cancer testing 423 
from a large and diverse sample of the UK consulting population. A risk gradient was found only in 424 
the case of an X-ray for lung cancer, with higher values reflecting greater risk. This was inconsistent 425 
with responses to the question of whether to be tested or not, which suggested risk affected testing 426 
preferences only in the case of colorectal cancer. More investigation is needed to understand how 427 
patients perceive and respond to risk in this context, and how best to develop the use of willingness-428 
to-pay techniques, which have the potential to provide good quality evidence which could enhance 429 
decision making in the provision of health care services. 430 
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Table 1. Summary of content of 12 vignettes: one for each combination of cancer and risk level 569 
 570 
 Colorectal  Lung  Pancreas  
symptoms for 1% 
risk 
Diarrhoea on most days Coughing on most 
days...unusually tired 
Some stomach pain 
on most days…lost a 
few ponds (~1.5-3kg) 
in weight 
symptoms for 2% 
risk 
Diarrhoea and stomach pain 
on most days 
Coughing on most days…a 
little out of breath walking up 
hills…lost a few pounds (~1.5-
3kg) in weight 
Some stomach pain 
on most days…lost 
half a stone (3.2kg) in 
weight 
symptoms for 5% 
risk 
Unusually tired…blood test 
shows anaemia  
Coughing on most 
days…coughed blood once 
Continuous stomach 
pain…lost half a 
stone (3.2kg) in 
weight 
symptoms for 10% 
risk 
Intermittent bleeding from 
the back passage (rectal 
bleeding)…blood test shows 
anaemia  
Coughing on most 
days…coughed blood a few 
times…lost half a stone 
(3.2kg) in weight  
Continuous stomach 
pain…lost 1 stone 
(6.4kg) in weight 
test/ 
investigation  
Colonoscopy  Chest x-ray  Ultrasound scan 
followed by CT scan  
treatment  Surgery and chemotherapy  “Difficult to treat” “Difficult to treat”  
prognosis/outlook Early diagnosis may improve 
outcome 
Early diagnosis may improve 
outcome  
Early detection does 
not necessarily 
improve survival 
 571 
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Table 2. Participant characteristics 574 
 575 
 
Characteristic 
 
                                        
                                                 Category 
           
                  n 
  
           % 
Age group  
n=3452 
40-59 1519 44.0 
60-69 945 27.4 
70+ 988 28.6 
Sex 
 n=3461 
male 1457 42.1 
female 2004 57.9 
Income 
n=2958 
<£10,000 720 24.3 
£10,000 - £25,000 1166 39.4 
£25,001 - £40,000 581 19.6 
£40,001 - £75,000 319 10.8 
>£75,000 172 5.8 
Ethnicity  
n=3453 
White British 3,096 89.7 
White Other 159 4.6 
Mixed 40 1.2 
Asian or Asian British 90 2.6 
Black or Black British 46 1.3 
Chinese 10 0.3 
Other Ethnic Group 12 0.4 
Education 
n=3388 
None 1,001 29.6 
GCSE or equivalent 781 23.1 
Vocational / ‘A’ level 850 25.1 
Degree and higher 756 22.3 
Employment 
n=3446 
Retired 1,673 48.5 
Not in paid employment 379 11.0 
Working part time 607 17.6 
Working full time 787 22.8 
Cancer diagnosis – self 
n=3463 
Yes 522 15.1 
No 2941 84.9 
Cancer – family/ close friend 
n=3465 
Yes 2597 75.0 
No 868 25.1 
Convenience of hospital 
n=3461 
Very convenient 1,388 40.1 
Quite convenient 1,621 46.8 
Quite inconvenient 323 9.3 
Very inconvenient 129 3.7 
Travel time to hospital 
n=3463 
<0.5 hour 1,759 50.8 
0.5 – 1 hour 1,458 42.1 
>1 hour 246 7.1 
 576 
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Table 3. Number (%) choosing to be investigated by cancer and risk level  577 
 578 
 Colorectal Lung Pancreas All three cancers (first 
vignette only) 
Risk 
level 
Number of 
responses 
Number (%) 
choosing to 
be tested 
Number of 
responses 
Number (%) 
choosing to 
be tested 
Number of 
responses 
Number (%) 
choosing to 
be tested 
Number of 
responses 
Number (%) 
choosing to 
be tested 
1% 572 462 (81%) 581 533 (92%) 582 525 (90%) 898 782 (87%) 
2% 569 485 (85%) 571 531 (93%) 580 527 (91%) 838 738 (88%) 
5% 580 496 (86%) 589 543 (92%) 572 526 (92%) 873 764 (88%) 
10% 570 508 (89%) 582 537 (92%) 582 529 (91%) 860 768 (89%) 
 2291 1951 (85%) 2323 2144 (92%) 2316 2107 (91%) 3469 3052 (88%) 
  579 
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 580 
Table 4. Number and percentage of respondents selecting each willingness-to-pay band by 581 
cancer (all responses) and by risk level (first response only).  582 
 583 
 
Colorectal Lung Pancreas 
All three 
cancers (first 
response only) 
£1-£100 630 (35%) 774 (39%) 691 (36%) 1,030 (37%) 
£101-£300 382 (21%) 400 (20%) 397 (20%) 541 (20%) 
£301-£700 186 (10%) 180 (9%) 197 (10%) 262 (9%) 
over £700 287 (16%) 278 (14%) 312 (16%) 405 (15%) 
would not pay 311 (17%) 346 (17%) 340 (18%) 527 (19%) 
 1,796 1,978 1,937 2,765 
     
 1% 2% 5% 10% 
£1-£100 295 (42%) 244 (36%) 242 (36%) 252 (36%) 
£101-£300 139 (20%) 127 (19%) 129 (19%) 146 (21%) 
£301-£700 58 (8%) 71 (10%) 62 (9%) 71 (10%) 
over £700 83 (12%) 102 (15%) 102 (15%) 118 (17%) 
would not pay 124 (18%) 137 (20%) 146 (21%) 120 (17%) 
 699 681 681 707 
 584 
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  586 
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 587 
Table 5. Mean (SD) and median (IQR) willingness-to-pay values, by cancer and risk level 588 
 589 
 n Mean (SD) £ Median (IQR) £ 
Colorectal    
1% 354 380 (348) 300 (100 to 700) 
2% 351 393 (351) 300 (100 to 700) 
5% 373 367 (351) 270 (100 to 700) 
10% 385 367 (343) 270 (100 to 700) 
 1463 377 (348) 300 (100 to 700) 
p-value  0.71  
    
Lung    
1% 401 305 (326) 100 (100 to 300) 
2% 403 339 (336) 270 (100 to 503) 
5% 399 360 (349) 270 (100 to 700) 
10% 412 365 (346) 270 (100 to 700) 
 1615 342 (340) 224 (100 to 670) 
p-value  0.049  
    
Pancreas    
1% 389 371 (355) 224 (100 to 700) 
2% 405 367 (336) 300 (100 to 700) 
5% 378 375 (352) 270 (100 to 700) 
10% 401 385 (358) 300 (100 to 700) 
 1573 374 (350) 270 (100 to 700) 
p-value  0.91  
    
all cancers (first response only)   
1% 567 312 (327) 100 (100 to 300) 
2% 534 366 (347) 270 (100 to 700) 
5% 529 360 (347) 270 (100 to 700) 
10% 573 377 (351) 270 (100 to 700) 
 2203 353 (344) 224 (100 to 700) 
p-value  0.0075  
 590 
 591 
NOTE: p-values were obtained from the one-way analysis of variance, with three degress of 592 
freedom, conducted to compare the effect of risk level on willingness-to-pay. 593 
 594 
 595 
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Table 6. Logistic regression: factors influencing the value of willingness-to-pay. Best fit logistic regression models for each cancer separately and all 
cancers together.   
 
£ All cancers together a  Colorectal (colonoscopy)  Lung (chest x-ray)  Pancreas (Ultrasound / CT scan) 
Variable (reference 
category) 
Coeff 
(se) 
p-
value 
95% CI  
Coeff 
(se) 
p-
value 
95% CI  
Coeff 
(se) 
p-
value 
95% CI  
Coeff 
(se) 
p-
value 
95% CI 
Cancer (colorectal)  0.0012              
Lung 
-50.80 
(18.67) 
0.0070 
(-87.43 to -
14.18) 
            
Pancreas 
8.56 
(19.37) 
0.6590 
(-29.44 to 
46.55) 
            
Risk (1%)  0.0206              
2% 
65.53 
(21.07) 
0.0020 
(24.21 to 
106.85) 
            
5% 
49.71 
(21.29) 
0.0200 
(7.95 to 
91.47) 
            
10% 
88.15 
(20.93) 
<0.0001 
(47.10 to 
129.20) 
 
            
Household Income 
(<£10,000) 
 <0.0001    <0.0001    <0.0001    <0.0001  
£10,000 - 
£25,000 
46.96 
(22.22) 
0.0350 
(3.39 to 
90.53) 
 
23.06 
(27.35) 
0.3990 
(-30.58 to  
76.71) 
 
48.75 
(26.63) 
0.0670 
(-3.48 to  
100.99) 
 
42.47 
(27.29) 
0.1200 
(-11.05 to 
96.00) 
>£25,000 
153.42 
(25.43) 
>0.0001 
(103.55 to  
203.30) 
 
132.99 
(28.73) 
<0.0001 
(76.62 to  
189.36) 
 
150.42 
(29.83) 
<0.0001 
(91.90 to  
208.93) 
 
145.28 
(28.86) 
<0.0001 
(88.66 to  
201.90) 
Education  <0.0001    <0.0001    0.0208    <0.0001  
GCSE or 
equivalent 
-21.07 
(23.59) 
0.3720 
(-67.33 to  
25.20) 
 
-9.85 
(28.87) 
0.7330 
(-66.50 to  
46.79) 
 
-0.22 
(27.73) 
0.9940 
(-54.61 to 
54.17) 
 
-41.75 
(28.49) 
0.1430 
-97.64 to 
14.14) 
A-level or 
equivalent 
21.48 
(22.91) 
0.3490 
(-23.46 to  
66.43) 
 
33.44 
(28.13) 
0.2350 
(-21.75 to  
88.62) 
 
35.68 
(27.42) 
0.1930 
(-18.10 to 
89.46) 
 
-17.51 
(28.02) 
0.5320 
-72.47 to 
37.45) 
Higher education 
95.22 
(24.36) 
<0.0001 
(47.44 to  
143.01) 
 
133.53 
(29.96) 
<0.0001 
(74.74 to  
192.31) 
 
72.97 
(29.08) 
0.0120 
(15.93 to 
130.01) 
 
86.06 
(29.78) 
0.0040 
(27.64 to 
144.49) 
Cancer diagnosis 
(yes) 
 0.0033    0.0048    0.0138    0.0092  
No 
-63.48 
(21.67) 
0.0030 
(-105.98 to 
-20.98) 
 
-73.04 
(25.93) 
0.0050 
(-123.92 to 
-22.17) 
 
-63.63 
(25.92) 
0.0140 
(-114.47 to 
-12.79) 
 
-70.71 
(27.18) 
0.0090 
(-124.02 to 
-17.39) 
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Employment 
(Retired) 
 0.0137        0.0488      
Not in paid 
employment 
-76.57 
(27.55) 
0.0060 
(-130.60 to 
-22.53) 
     
-82.45 
(32.22) 
0.0100 
(-145.64 to 
-19.25) 
    
Working part time 
-40.55 
(21.33) 
0.0570 
(-82.37 to 
1.27) 
     
-43.00 
(25.33) 
0.0900 
(-92.70 to 
6.70) 
    
Working full time 
-3.39 
(21.22) 
0.8730 
(-45.01 to 
38.23) 
     
-20.24 
(23.86) 
0.3960 
(-67.05 to 
26.57) 
    
Family cancer (yes)          0.0276      
No         
-46.89 
(21.36) 
0.0280 
-88.78 to -
5.00) 
    
Sex (male)              0.0298  
Female             
-40.09 
(18.49) 
0.0300 
-76.37 to -
3.81) 
 
 
a Based on first response only to avoid mote than one respinse from each participant   
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Figure 1. Schema illustrating the two-part willingness to pay exercise. Choice of payment scale 
leads to a bidding process with the starting point randomly generated from four values within 
the band. 
 
 
 
 
 
 
 
 
 
Figure 2. Screen shot of the payment scale exercise showing the use of reference goods.  
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Appendix A. Screen shots showing questions about participant characteristics. 
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 Figure 1 Click here to download Figure figure_1.pdf 
 Figure 2 Click here to download Figure figure_2.pdf 
